Monte Rosa Therapeutics (GLUE) Consolidated Net Income (2023 - 2025)
Historic Consolidated Net Income for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.1 million.
- Monte Rosa Therapeutics' Consolidated Net Income fell 1350.43% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 11751.67%. This contributed to the annual value of -$72.7 million for FY2024, which is 4626.6% up from last year.
- Latest data reveals that Monte Rosa Therapeutics reported Consolidated Net Income of -$27.1 million as of Q3 2025, which was down 1350.43% from -$12.3 million recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Consolidated Net Income registered a high of $46.9 million during Q1 2025, and its lowest value of -$35.2 million during Q2 2023.
- Its 3-year average for Consolidated Net Income is -$18.2 million, with a median of -$30.3 million in 2024.
- Over the last 5 years, Monte Rosa Therapeutics' Consolidated Net Income had its largest YoY gain of 24658.43% in 2025, and its largest YoY loss of 1350.43% in 2025.
- Over the past 3 years, Monte Rosa Therapeutics' Consolidated Net Income (Quarter) stood at -$33.3 million in 2023, then surged by 140.32% to $13.4 million in 2024, then tumbled by 301.99% to -$27.1 million in 2025.
- Its Consolidated Net Income stands at -$27.1 million for Q3 2025, versus -$12.3 million for Q2 2025 and $46.9 million for Q1 2025.